aTyr Pharma, Inc.(US:ATYR) Businesswire·2025-10-12 13:09Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of securities law violations related to misleading statements about the efficacy of its drug, efzofitimod, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal options [1]. - There is a deadline of December 9, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against aTyr [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [6]. Group 2: Allegations Against aTyr Pharma - The complaint alleges that aTyr and its executives made false and misleading statements regarding the drug efzofitimod, particularly about its ability to allow patients to taper off steroids completely [4]. - The EFZO-FIT study results indicated that efzofitimod did not show a significant change in mean daily oral corticosteroid dose at week 48, with a reduction of only 2.79 mg for the drug compared to 3.52 mg for placebo [5]. - Following the release of these results, aTyr's stock plummeted by 83.25%, dropping from $6.03 to $1.01 [5]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding aTyr's conduct [7].